Benitec Biopharma Inc (BNTC)

Over the past six months, Benitec Biopharma Inc.'s stock price has declined. As of March 23, 2026, the share price was $11.19, a 21.97% decrease from $14.34 on March 24, 2025. The stock's 52-week range has been between $9.85 and $17.15. In March 2026, the stock price reached a high of $13.390 and a low of $10.150, and as of March 27, 2026, it was down 5.78% for the month and 23.76% year-to-date. Recent events impacting the stock include positive interim Phase 1b/2a results for BB-301, announced on March 9, 2026, at the Muscular Dystrophy Association Clinical & Scientific Conference. The company also hosted an industry forum breakfast event at the same conference on March 10, 2026, to highlight the progress of BB-301. Additionally, Benitec Biopharma released its Second Quarter 2026 Financial Results and provided an operational update on February 12, 2026.

As a clinical-stage biotechnology company, Benitec Biopharma's products and services are not yet commercially available, and therefore, traditional demand seasonality does not apply. However, historical data indicates some seasonality in the company's stock performance. February has been the strongest month, with an average return of 7.19%, while June has been the weakest, averaging an -11.81% return. This stock seasonality is based on 12 years of historical price data and has a consistency score of 45.2 (Poor).

Benitec Biopharma, Inc. is a clinical-stage biotechnology company focused on advancing genetic medicines, operating in the Healthcare sector, specifically in Biotechnology and Pharmaceutical Preparation Manufacturing. Their proprietary platform, ddRNAi, integrates RNA interference with gene therapy to silence disease-causing genes and deliver wildtype replacement genes. The company's primary product candidate, BB-301, is an AAV-based gene therapy developed to treat OPMD and has received Orphan Drug Designation in the United States and the European Union.

Benitec Biopharma Inc. is headquartered in Hayward, California, United States, and was founded in Australia in 1997.

Benitec Biopharma's reputation has likely been positively influenced by the announcement of positive interim Phase 1b/2a results for its lead product candidate, BB-301, for OPMD. These results, presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, highlight continued progress for BB-301, which is currently the only clinical-stage therapeutic in development for OPMD.

Benitec Biopharma Inc. has a significant number of institutional owners. As of December 2025, there were 72 institutional filers holding a collective stake of 0.8% in the company, an increase from 0.5% in September 2025. These institutions hold a total of 31,771,500 shares. Major institutional owners include Suvretta Capital Management, LLC, Janus Henderson Group Plc, Franklin Resources Inc, Adage Capital Partners Gp, L.l.c., Ra Capital Management, L.p., Vanguard Group Inc, Nantahala Capital Management, LLC, BlackRock, Inc., Infinitum Asset Management, Llc and Siren, L.L.C.